Karlsson MO - Search Results

1

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Xie R, et al. Among authors: karlsson mo. J Clin Oncol. 2002 Aug 1;20(15):3293-301. doi: 10.1200/JCO.2002.11.073. J Clin Oncol. 2002. PMID: 12149304

2

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J, Karlsson MO. Sandström M, et al. Among authors: karlsson mo. J Clin Oncol. 1996 May;14(5):1581-8. doi: 10.1200/JCO.1996.14.5.1581. J Clin Oncol. 1996. PMID: 8622075

3

The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.

Karlsson MO, Wade JR, Loumaye E, Munafo A. Karlsson MO, et al. Br J Clin Pharmacol. 1998 Jan;45(1):13-20. doi: 10.1046/j.1365-2125.1998.00644.x. Br J Clin Pharmacol. 1998. PMID: 9489588 Free PMC article. Clinical Trial.

4

Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria.

Sidhu JS, Ashton M, Huong NV, Hai TN, Karlsson MO, Sy ND, Jonsson EN, Cong LD. Sidhu JS, et al. Among authors: karlsson mo. Br J Clin Pharmacol. 1998 Apr;45(4):347-54. doi: 10.1046/j.1365-2125.1998.t01-1-00686.x. Br J Clin Pharmacol. 1998. PMID: 9578181 Free PMC article.

5

Pharmacokinetic models for the saturable distribution of paclitaxel.

Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Karlsson MO, et al. Drug Metab Dispos. 1999 Oct;27(10):1220-3. Drug Metab Dispos. 1999. PMID: 10497151

6

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. van Zuylen L, et al. Among authors: karlsson mo. Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18. doi: 10.1007/s002800000215. Cancer Chemother Pharmacol. 2001. PMID: 11345647 Clinical Trial.

7

Mechanism-based pharmacokinetic model for paclitaxel.

Henningsson A, Karlsson MO, Viganò L, Gianni L, Verweij J, Sparreboom A. Henningsson A, et al. Among authors: karlsson mo. J Clin Oncol. 2001 Oct 15;19(20):4065-73. doi: 10.1200/JCO.2001.19.20.4065. J Clin Oncol. 2001. PMID: 11600609 Clinical Trial.

8

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.

Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Xie R, et al. Among authors: karlsson mo. Clin Pharmacol Ther. 2002 Sep;72(3):265-75. doi: 10.1067/mcp.2002.126741. Clin Pharmacol Ther. 2002. PMID: 12235447

9

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Friberg LE, et al. Among authors: karlsson mo. J Clin Oncol. 2002 Dec 15;20(24):4713-21. doi: 10.1200/JCO.2002.02.140. J Clin Oncol. 2002. PMID: 12488418

10

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.

Henningsson A, Sparreboom A, Sandström M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO. Henningsson A, et al. Among authors: karlsson mo. Eur J Cancer. 2003 May;39(8):1105-14. doi: 10.1016/s0959-8049(03)00126-6. Eur J Cancer. 2003. PMID: 12736110

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

435 results

Search Page

Filters